Slovak pharma multinationals' association elects new board
This article was originally published in Scrip
Slovakia’s association of research-based pharmaceutical companies (SAFS) has elected a new board. Dr Pavol Trnovec of GlaxoSmithKline, who was previously its vice-chairman, will lead SAFS as chairman. He replaces Dr Miroslav Lednar of Sanofi-Aventis, who remained on the board; he will supervise SAFS members' compliance with ethical requirements in marketing.